Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL-IV in treatment-naive adults with genotype 1a chronic hepatitis C
2012-005522-29Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of paritaprevir, ritonavir, glecaprevir, dasabuvir and ribavirin in hepatitis C virus infection (2 arms), sponsored by AbbVie Inc. Primary endpoint: Sustained virologic response at 12 weeks. Started Apr 2013; status: completed.
02
Drugs
paritaprevirritonavirglecaprevirdasabuvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2012-005522-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005522-29.